Insider Transactions in Q1 2023 at Quest Diagnostics Inc (DGX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 24
2023
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
170
-4.66%
|
$22,780
$134.25 P/Share
|
|
Mar 24
2023
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-0.8%
|
$13,266
$134.25 P/Share
|
|
Mar 07
2023
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
4,754
-10.98%
|
$665,560
$140.55 P/Share
|
|
Mar 07
2023
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
5,307
-7.26%
|
$742,980
$140.55 P/Share
|
|
Mar 06
2023
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,841
-8.15%
|
$564,627
$147.86 P/Share
|
|
Mar 06
2023
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,595
+15.43%
|
$1,263,465
$147.86 P/Share
|
|
Mar 06
2023
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
682
-2.0%
|
$100,254
$147.86 P/Share
|
|
Mar 06
2023
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,918
+5.31%
|
$281,946
$147.86 P/Share
|
|
Mar 06
2023
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
799
-6.07%
|
$117,453
$147.86 P/Share
|
|
Mar 06
2023
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
2,579
+16.4%
|
$379,113
$147.86 P/Share
|
|
Mar 06
2023
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
4,610
-5.93%
|
$677,670
$147.86 P/Share
|
|
Mar 06
2023
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
9,917
+11.32%
|
$1,457,799
$147.86 P/Share
|
|
Mar 06
2023
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
38,604
-9.02%
|
$5,674,788
$147.86 P/Share
|
|
Mar 06
2023
|
Stephen H Rusckowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
82,631
+16.18%
|
$12,146,757
$147.86 P/Share
|
|
Mar 06
2023
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,036
-7.26%
|
$1,181,292
$147.86 P/Share
|
|
Mar 06
2023
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
15,204
+12.08%
|
$2,234,988
$147.86 P/Share
|
|
Mar 06
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
583
-4.93%
|
$85,701
$147.86 P/Share
|
|
Mar 06
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
1,985
+14.37%
|
$291,795
$147.86 P/Share
|
|
Mar 03
2023
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
717
-1.05%
|
$100,380
$140.63 P/Share
|
|
Mar 02
2023
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
593
-1.52%
|
$81,834
$138.54 P/Share
|
|
Mar 01
2023
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,496
-1.0%
|
$489,440
$140.69 P/Share
|
|
Mar 01
2023
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
320
-0.81%
|
$44,800
$140.69 P/Share
|
|
Mar 01
2023
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
90
-0.84%
|
$12,600
$140.69 P/Share
|
|
Mar 01
2023
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,292
-1.34%
|
$180,880
$140.69 P/Share
|
|
Mar 01
2023
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
392
-0.57%
|
$54,880
$140.69 P/Share
|
|
Mar 01
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
65
-0.66%
|
$9,100
$140.69 P/Share
|
|
Mar 01
2023
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
68
-0.21%
|
$9,520
$140.69 P/Share
|
|
Feb 24
2023
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
1,415
-3.46%
|
$199,515
$141.42 P/Share
|
|
Feb 24
2023
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
1,690
-2.39%
|
$238,290
$141.42 P/Share
|
|
Feb 23
2023
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
17,443
+15.27%
|
-
|
|
Feb 23
2023
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,473
-1.82%
|
$216,531
$147.86 P/Share
|
|
Feb 23
2023
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,710
+18.77%
|
-
|
|
Feb 23
2023
|
Stephen H Rusckowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,059
+5.43%
|
-
|
|
Feb 23
2023
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,826
-1.74%
|
$856,422
$147.86 P/Share
|
|
Feb 23
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,094
+17.45%
|
-
|
|
Feb 23
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
195
-2.44%
|
$28,665
$147.86 P/Share
|
|
Feb 23
2023
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
498
+1.52%
|
-
|
|
Feb 23
2023
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
188
-0.59%
|
$27,636
$147.86 P/Share
|
|
Feb 23
2023
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
1,919
+15.26%
|
-
|
|
Feb 23
2023
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
245
-2.73%
|
$36,015
$147.86 P/Share
|
|
Feb 23
2023
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,442
+5.64%
|
-
|
|
Feb 23
2023
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
811
-2.07%
|
$119,217
$147.86 P/Share
|
|
Feb 23
2023
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,919
+34.46%
|
-
|
|
Feb 23
2023
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
3,838
+5.16%
|
-
|
|
Feb 23
2023
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
962
-1.42%
|
$141,414
$147.86 P/Share
|
|
Feb 23
2023
|
Mark A Gardner SVP of Molecular Gen & Oncol |
BUY
Grant, award, or other acquisition
|
Direct |
1,919
+39.65%
|
-
|
|
Feb 01
2023
|
Vicky B Gregg Director |
BUY
Small Acquisition
|
Direct |
64
+0.37%
|
$9,344
$146.75 P/Share
|
|
Feb 01
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Small Acquisition
|
Direct |
13
+0.16%
|
$1,898
$146.75 P/Share
|
|
Feb 01
2023
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Small Acquisition
|
Direct |
27
+0.3%
|
$3,942
$146.75 P/Share
|